Ebola Outbreak: Uganda Set To Start Vaccine Trials

Updated Feb 3, 2025 | 08:58 AM IST

SummaryAfter a nurse died of the Ebola virus, the country has declared Ebola outbreak and is now deploying vaccine against the Sudan strain of the virus.
Ebola vaccines

On Thursday, Uganda confirmed an outbreak of the Ebola virus in its capital city Kampala, with the first confirmed patient dying from it a day before. As per the new developments, the officials are now preparing to deploy a trial vaccine to put an end to this outbreak.

Groups of scientists are working on the vaccine and deployment of more than 2,000 doses of a candidate vaccine against the Sudan strain of Ebola has been planned and confirmed by the Uganda Virus Research Institute. As per the World Health Organization (WHO), Uganda has access to 2,169 doses of trial vaccine. For now, however, there are no approved vaccines for the strain and officials are still investigating the source of the outbreak.

The WHO had also allocated $1 million from its contingency fund for emergencies to support quick action and contain the outbreak in the country.

Confirmed Case

On Wednesday, the Sudan strain of Ebola killed a nurse employed at Kampala's main referral hospital. It is after his death that Ebola was declared an outbreak in the country. Post-mortem samples too have confirmed the Sudan Ebola Virus Disease and at least 44 contacts of the deceased man have been listed for tracing. 30 of these are health workers.

Ebola is a highly infectious hemorrhagic fever, which is transmitted through contact with bodily fluids and tissue. Symptoms include headache, vomiting of blood, muscle pains and bleeding.

it was in the late 2022, when Uganda had last suffered an Ebola outbreak. It killed 55 of the 143 people who were infected and was declared over on January 11, 2023.

What Is Ebola Virus Disease?

As per the WHO, Ebola virus disease (EVD) is a rare but severe illness in humans and is often fatal. People can get infected with the virus if they touch an infected animal when preparing food, or touch body fluids of an infected person such as saliva, urine, faeces or semen, or things that have body fluids of an infected person like clothes or sheets.

How Does Transmission Work?

Ebola enters the body through cuts in the skin or when one is touching their eyes, nose or mouth. Early symptoms include fever, fatigue and headache.

It was first discovered in 1976 in two simultaneous outbreak, when in Nzara, South Sudan and other in Yambuku, Democratic Republic of Congo. The latter occurred near a village near the Ebola River, which is where it gets its name from.

It is highly infectious and transmissible disease, in fact, there have been cases of health-care workers who have frequently been infected while treating patients with suspected or confirmed Ebola. This occurs through close contact with patients when infection control precautions are not practiced strictly.

Cases of people conducted burial ceremonies, involving direct contact with the body of the deceased too can lead to the transmission of Ebola. Even after the long suffering and recovery, there is a possibility of sexual transmission. Pregnant women who get acute Ebola and recover may still carry the virus in their breastmilk, or in pregnancy related fluids and tissues.

Symptoms:

  • feeling tired
  • headache
  • muscle and joint pain
  • eye pain and vision problems
  • weight gain
  • belly pain and loss of appetite
  • hair loss and skin problems
  • trouble sleeping
  • memory loss
  • hearing loss
  • depression and anxiety

End of Article

PJ.2.1 Is Now Variant Under Monitoring After Detection In 18 Countries: Should You Worry About Its 24 Mutations?

Updated Nov 20, 2026 | 11:00 PM IST

SummaryThe WHO has designated COVID-19 variant PJ.2.1, which has 24 spike protein changes, as a Variant Under Monitoring after sequences were reported from 18 countries. It currently assesses its additional global public health risk as low, but says more data are needed to determine whether it causes more severe illness.
PJ.2.1 Is Now Variant Under Monitoring After Detection In 18 Countries: Should You Worry About Its 24 Mutations?

Credit: iStock

The World Health Organization (WHO) has designated COVID-19 variant PJ.2.1, a descendant of the JN.1 lineage with 24 spike protein changes, as a Variant Under Monitoring (VUM). As of November 8, the variant had been detected in 18 countries, with its share of reported sequences increasing particularly in Canada and the United States.

"Considering the available evidence, the additional public health risk posed by PJ.2.1 is evaluated as low at the global level, with low confidence," the WHO said in its initial risk evaluation published by its Technical Advisory Group on Virus Evolution (TAG-VE).

Laboratory findings suggest that the variant does not show substantial additional antibody escape compared with other circulating variants. Blood samples from recipients of LP.8.1- and XFG-adapted vaccines were also able to neutralize it in laboratory tests.

However, there is insufficient clinical data to determine whether PJ.2.1 causes more severe illness.

What Is COVID Variant PJ.2.1? How Widely Has It Spread?

Also read: New COVID Variant PJ.2.1 Spreading Globally: Is India At Risk, Are There New Symptoms?

According to the WHO report, "PJ.2.1 is a highly mutated variant with 24 amino acid differences in the Spike protein alone."

First identified in Canada, laboratory studies indicate that it binds more strongly to human ACE2 receptors, which the virus uses to enter cells. However, stronger receptor binding does not necessarily mean faster transmission between people.

The WHO noted that increased receptor binding "may contribute to the observed growth, but do not directly establish increased transmissibility in humans."

The proportion of PJ.2.1 among available global sequences increased from 1% in epidemiological week 33 to 11.6% in week 41, according to the WHO.

As of November 8, 2026, 722 sequences had been submitted to the GISAID, an open access database, from 18 countries.

Can Existing Vaccines Protect Against PJ.2.1?

Read More: New COVID-19 Variant PJ.2.1 Spreads Globally: WHO Says Symptoms Resemble Cold, Flu

In a study involving plasma from 36 recipients of an LP.8.1-adapted vaccine, researchers found no greater antibody evasion against PJ.2.1 than against most tested variants.

Another study involving 22 participants found that neutralisation titres against PJ.2.1 increased 2.8-fold, from 228 before vaccination to 642, at a median of 14 days after an XFG-adapted mRNA vaccine.

These findings suggest that vaccine-induced antibodies can neutralize PJ.2.1 in laboratory tests. However, they do not establish real-world vaccine effectiveness against infection or severe disease, the WHO report said.

Does PJ.2.1 Cause More Severe Disease?

"There is currently no evidence establishing greater disease severity associated with PJ.2.1, although comparative clinical data remain limited," the WHO said.

The agency has called for further studies to assess vaccine effectiveness, compare hospitalisations and severe disease outcomes, evaluate antiviral susceptibility and strengthen genomic surveillance.

Dr Gopakumar, Senior Consultant and Head of the Department of Internal Medicine at Apollo Adlux Hospital, Kerala, said the number of mutations alone does not determine how dangerous a variant is.

"The emergence of the new COVID-19 variant PJ.2.1 highlights the virus’s continued ability to evolve. While the reported 24 mutations, particularly in the spike protein, have attracted attention, the number of mutations alone does not determine how dangerous a variant is. What matters clinically is whether these changes make the virus more transmissible, help it evade existing immunity or increase the risk of severe illness," he told HealthandMe.

Dr Navneet Sood, Associate Director and Senior Consultant, Pulmonology, Dharamshila Narayana Superspeciality Hospital, Delhi, added that current evidence does not indicate an increased impact on disease severity compared with previous variants.

"While it is safe to say that the evidence currently shows that there is no increased impact of PJ.2.1 compared to previous variants in disease severity, the WHO's variant surveillance system is still monitoring the potential for new variants to emerge and experts have emphasized the need for genomic monitoring. Public awareness should be centred on identifying respiratory symptoms, testing if required, and taking additional precautions for vulnerable people," he told HealthandMe.

Should You Be Worried?

The WHO currently assesses the additional global public health risk from PJ.2.1 as low, although confidence in this assessment remains limited.

There is no need to panic, but experts advise people to remain vigilant. Older adults, immunocompromised individuals and those with chronic illnesses should take particular care. Maintaining respiratory hygiene, ensuring adequate ventilation and seeking medical advice if respiratory symptoms develop remain sensible precautions.

End of Article

Antibiotics Are Not Painkillers: Why You Shouldn't Take Them For Fever Or Viral Infections

Updated Nov 20, 2026 | 10:00 PM IST

SummaryAntibiotics cannot treat viral infections such as colds and flu. Experts warn that ​Self-medicating, using leftover antibiotics or taking them without a prescription can accelerate resistance and make future bacterial infections harder to treat.
Antibiotics Are Not Painkillers: Why You Shouldn't Take Them For Fever Or Viral Infections

Credit: iStock

Fever, body ache, sore throat or cough? Taking an antibiotic may seem like a quick fix, but it can do more harm than good. Antibiotics treat bacterial infections, not viral illnesses such as colds and flu.

During World Antimicrobial Resistance (AMR) Awareness Week, experts have warned against self-medication, buying antibiotics over the counter and changing prescribed treatment without medical advice. Such practices fuel antimicrobial resistance (AMR), making infections harder to treat.

Dr Jatin Ahuja, Consultant, Infectious Diseases, Indraprastha Apollo Hospital, Delhi, told HealthandMe that resistance is making common bacterial infections increasingly difficult to treat.

"When bacteria develop resistance to multiple classes of antibiotics, fewer effective treatment options remain. This can delay recovery, increase complications and prolong hospital stays. Pneumonia, urinary tract infections and bloodstream infections become particularly challenging when bacteria do not respond to commonly used drugs," he said.

Can Antibiotics Treat Fever, Cold, Flu Or Body Ache?

Also read: ICMR Flags Widespread Antibiotic Resistance Across India: From E. coli To Typhoid, Which Drugs Are Failing?

Fever, pain or a sore throat does not automatically mean you need antibiotics.

"Taking antibiotics for viral infections, particularly coughs, colds and flu, does not help recovery," Dr Ahuja said.

Dr Sumit Jain, Director – Internal Medicine, Paras Health, Panchkula, said antibiotics are ineffective against viral infections.

"People will often think that antibiotics are the answer to a fever, body ache, cold, cough or sore throat. They're not. Antibiotics only work against bacterial infections and are of no use at all against viral infections (i.e. the common cold, flu and most of the seasonal respiratory infections)," he told HealthandMe.

Dr Atul Kakar, Chairperson, Internal Medicine, Sir Ganga Ram Hospital, explained that the common cold, flu, most sore throats and many cases of acute bronchitis are caused by viruses.

Viral fevers are generally self-limiting and may resolve within three to seven days with rest, hydration and symptom relief. Antibiotics do not speed up recovery, he told HealthandMe.

How Does Antibiotic Misuse Cause Drug Resistance?

Read More: 98 Years After Penicillin: Are We Running Out Of Effective Antibiotics?

Antibiotic resistance develops when bacteria evolve to survive medicines designed to kill them or stop their growth. Inappropriate antibiotic use accelerates this process.

Dr Ahuja warned that resistance to multiple antibiotics leaves doctors with fewer treatment options, increasing the risk of complications and prolonged hospital stays.

Dr Kakar added that resistant bacteria can spread between people at home, in workplaces and in hospitals, making AMR a wider public health threat.

Drug-Resistant Infections Raise Mortality Risk

A recent Indian Council of Medical Research (ICMR) study across 20 tertiary-care hospitals found that 61.1% of confirmed infections caused by four major Gram-negative bacteria were carbapenem-resistant.

Published in The Lancet Regional Health – Southeast Asia, the study analysed nearly 1.6 lakh hospitalised patients between April 2022 and April 2025. Patients with resistant infections faced higher mortality, longer hospital stays and substantially higher treatment costs.

The global picture is equally concerning. According to the World Health Organization (WHO), one in six laboratory-confirmed bacterial infections worldwide is already resistant to antibiotics. If current trends persist, drug-resistant infections could contribute to more than 39 million deaths by 2050.

When Should You Take Antibiotics?

Antibiotics should be taken only when a doctor diagnoses or strongly suspects a bacterial infection.

Dr Ahuja recommended clinical assessment and culture and sensitivity testing, wherever indicated, to identify the bacteria and determine which medicines are likely to work.

Vaccination, hand hygiene and infection-control measures can also help prevent infections and reduce antibiotic use.

What Are The Risks Of Taking Antibiotics Without A Prescription?

Self-medicating, using leftover antibiotics or taking them without a prescription can accelerate resistance and make future bacterial infections harder to treat.

Dr Jain also warned of side effects, including diarrhoea, allergic reactions and disruption of normal gut flora.

He advised against self-medication and recommended consulting a doctor if symptoms persist or worsen.

Antibiotics are not a quick fix for every fever, cough or body ache. Use them only when medically necessary to help keep these medicines effective.

End of Article

US Loses Measles-Free Status: Doctors Warn Of Mumps, Rubella And Whooping Cough Resurgence

Updated Nov 20, 2026 | 06:00 PM IST

SummaryAfter US lost its measles elimination status after 26 years, doctors have warned that the declining vaccination rates could bring back mumps, rubella, whooping cough and potentially other infections, including polio. Experts are calling for stronger vaccination coverage, disease surveillance and public trust to prevent further outbreaks.
US Loses Measles-Free Status: Doctors Warn Of Mumps, Rubella And Whooping Cough Resurgence

Credit: iStock

The US has lost its measles elimination status after maintaining it for about 26 years. Doctors now warn that declining vaccination rates could trigger a resurgence of other vaccine-preventable diseases, including mumps, rubella and whooping cough.

Measles is highly contagious but preventable with two doses of the measles, mumps and rubella (MMR) vaccine. However, declining vaccination coverage and anti-vaccine rhetoric from US President Donald Trump and Health Secretary Robert F. Kennedy Jr. have raised concerns about the country's ability to contain outbreaks.

Experts fear measles could be the first of several preventable diseases to return.

"This resurgence is an early warning signal demonstrating that vaccination, surveillance, and public trust have all eroded and other preventable diseases are likely to follow," said Rochelle Walensky, who led the Centers for Disease Control and Prevention (CDC) from 2021 to 2023.

Tom Frieden, who headed the CDC from 2009 to 2017, called measles "like a canary in the coal mine for other vaccine-preventable illnesses", warning that it may not be the last disease to resurface, CIDRAP News reported.

The US outbreak has caused more than 5,000 cases and 11 deaths. Declining vaccination coverage and imported cases linked to international travel have added to the spread.

Mumps And Rubella Could Return

Also read: US Set To Lose Measles-Elimination Status After 26 Years: Prof Devi Sridhar Explains Reasons Behind Resurgence

Falling MMR vaccination coverage could also leave Americans vulnerable to mumps and rubella.

Cases of both infections could rise over the next several years, predicted William Schaffner, an infectious disease physician at Vanderbilt Medical Center and spokesperson for the Infectious Diseases Society of America.

He expects mumps to emerge first, given its higher global prevalence. Earlier this year, San Diego State University reported an outbreak among its football team.

Professor Peter Hotez of Texas Children's Hospital warned that measles was just "the first domino to fall".

"I also expect congenital rubella birth defects to return, as well as pertussis next year," he said.

Whooping Cough Raises Particular Concern

Experts are particularly concerned about pertussis, or whooping cough, as coverage of the diphtheria, tetanus and pertussis (DTaP) vaccine has also declined.

"Whooping cough has a vivid name, and it deserves it," Schaffner said. The bacterial infection inflames the airways, causing breathing difficulties and intense coughing bouts that can produce a distinctive "whoop" sound.

Schaffner recalled diagnosing a young adult based on the sound of their cough alone during his early years as a physician.

Hotez warned that measles could also become a recurring seasonal threat. "Now that measles has returned, we should expect annual late winter to early spring surges just like we did in the pre-vaccine era, and as we've now seen in 2025-2026," he said.

Read More: What Happens After Measles Infection? The Hidden Risks That Can Last For Years

Polio And Chickenpox Also Raise Concerns

Schaffner is also watching for a possible rise in tetanus cases because the vaccine protecting against whooping cough is administered alongside tetanus and diphtheria protection.

He also flagged chickenpox, which spreads rapidly among unvaccinated children.

In 2022, an unvaccinated 20-year-old man in Rockland County, New York, contracted polio and developed paralysis.

"It's very distressing, because there is a strong element of turning back the clock, or the calendar, to the bad old days," Schaffner said.

He blamed messaging from Washington that has undermined confidence in vaccines and contributed to growing scepticism.

What Can The US Do Now?

Hotez suggested considering a three-dose MMR schedule starting at six months, instead of the current recommended starting age of 12 months. He also said some adults born before 1989 may need a second dose.

To regain measles elimination status, the US must interrupt transmission for at least 12 consecutive months before submitting a plan to the World Health Organization (WHO).

Restoring vaccination coverage, strengthening disease surveillance and rebuilding public trust will be essential to preventing further outbreaks.

End of Article